Can Semaglutide Affect Your Liver?

The biggest misconception: that semaglutide is hard on the liver

If you have come to this page feeling concerned, that concern is understandable. Many weight-loss medicines have carried liver warnings over the years, so assuming the same of a GLP-1 is a natural leap. It turns out, though, that the evidence runs in the opposite direction.

The liver condition most closely connected to obesity is metabolic dysfunction-associated steatotic liver disease (MASLD), and its more serious form, MASH (metabolic dysfunction-associated steatohepatitis), which involves inflammation and, in advanced cases, fibrosis. Semaglutide has been studied specifically in this context. Clinical trials demonstrated meaningful reductions in liver fat and in markers of liver inflammation among participants using the medicine alongside lifestyle changes.

The strongest signal came when, on 3 July 2026, the MHRA granted conditional approval for Wegovy to treat MASH with moderate-to-advanced fibrosis in eligible adults. The UK became one of the first countries in the world to sanction a GLP-1 medicine for a liver indication. That approval followed a rigorous regulatory process — the kind that does not happen if a medicine is causing the liver harm. You can read the GOV.UK announcement semaglutide approved to treat form of liver disease.

So the myth (that semaglutide damages the liver) is not supported by the available evidence. If you want a fuller picture of how Wegovy can affect your liver, including what the trial data shows and what to watch for, that is covered in detail on a dedicated page.

What does semaglutide actually do to the liver during weight-loss treatment?

Semaglutide is a GLP-1 receptor agonist. By slowing gastric emptying and reducing appetite, it drives a meaningful calorie deficit and, over time, reduces visceral and liver fat. Less fat reaching or accumulating in the liver appears to be the main mechanism behind the improvements seen in liver markers. The NHS medicines page on semaglutide covers the medicine's general profile in plain language.

In the context of the MASH trial, benefits were seen in histological improvement (meaning changes visible under microscopy in liver tissue) not just in surrogate markers. That is a clinically meaningful bar to clear.

For people using semaglutide purely for weight management, the liver implications are mostly indirect: as body weight falls, particularly fat around and within the liver, liver function tests often improve. This is not guaranteed and varies between individuals, but it is the pattern observed across the weight-loss trial programme.

One nuance worth knowing: as with some other medicines, modest and transient changes in liver enzymes have been reported in a small number of people. These are generally not clinically significant but are one reason why disclosing any existing liver condition during your consultation matters. If you want to explore semaglutide's liver effects in more detail, the question of how semaglutide affects the liver is covered further on a dedicated page.

What remains uncertain, and who should be especially careful

Honest medicine means acknowledging limits. The MASH approval is conditional, meaning data collection and review continue. Most of the weight-management trial population did not have advanced liver disease at baseline, so the picture for people with cirrhosis or decompensated liver function is less established. Current prescribing guidance does not recommend semaglutide for those with severe hepatic impairment, and a specialist hepatologist's input is appropriate in that situation.

There is also the question of gallbladder health. Rapid weight loss, through any mechanism, can increase the risk of gallstones, and the NHS patient information for semaglutide lists gallbladder problems among the side effects to be aware of. Pain in the upper right abdomen, particularly if it radiates or is accompanied by fever, warrants prompt medical attention rather than waiting for a scheduled check-in.

Pregnancy, breastfeeding and trying to conceive: semaglutide is not recommended in any of these situations. If you are pregnant or planning to conceive, please speak to your GP before starting or continuing treatment. Contraception guidance during treatment is worth discussing with a prescriber; there is more detail on this in the context of the use of Wegovy and pregnancy.

If you have any form of liver disease (diagnosed or suspected) bring it to the consultation. A prescriber cannot make a sound clinical decision without that information, and it protects you.

What this means for accessing semaglutide in the UK

Semaglutide for weight management is prescribed as Wegovy, a once-weekly injection licensed for adults with a BMI of 30 or above, or 27 and over with at least one weight-related condition. It is not available to buy without going through a clinical assessment by a qualified prescriber. That gate exists precisely because medicines like this interact with your whole health picture, including liver health.

At nume, a GPhC-registered prescriber reads your consultation personally before anything is dispensed. If liver concerns come up during that review, they are factored into the decision. You can see our clinical team's approach on the clinical team page.

The MHRA's new liver-disease approval is one of the more significant regulatory developments in GLP-1 medicine over the past year. It does not change how Wegovy is prescribed for weight management, but it does tell a clearer story about where the liver evidence is heading. A related question that comes up in consultations is whether elderly patients can lose weight on semaglutide, and that is explored separately for anyone whose situation or that of a relative falls into that category. The cost of Wegovy in the UK and what to expect from a private prescription are covered separately if that is the next question on your mind.

If you are ready to explore whether treatment is clinically suitable for you, a free consultation is the right first step.

Check your eligibility